340
Participants
Start Date
March 23, 2015
Primary Completion Date
August 31, 2020
Study Completion Date
February 24, 2025
Palbociclib
Palbociclib, 125mg, orally once daily on Day 1 to Day 21 of every 28-day cycle followed by 7 days off treatment
Letrozole
Letrozole, 2.5mg, orally once daily (continuously)
Placebo
Placebo, 125mg, orally once daily on Day 1 to Day 21 of every 28-day cycle followed by 7 days off treatment
Letrozole
Letrozole, 2.5mg, orally once daily (continuously)
National Taiwan University Hospital, Taipei
Taipei Medical University Hospital/ Department of Surgery, Taipei
Taipei Municipal Wanfang Hospital (Managed by Taipei Medical University ), Taipei
National Cheng Kung University Hospital / Internal Medicine, Tainan City
King Chulalongkorn Memorial Hospital, Pathumwan
Chula Clinical Research Center (Chula CRC), Patumwan
Ramathibodi Hospital, Mahidol University, Bangkok
Oncology Unit, Department of Internal Medicine, Phramongkutklao Hospital, Bangkok
Mackay Memorial Hospital, Taipei
Division of Medical Oncology, Department of Medicine,, Bangkok
Taipei Veterans General Hospital/Surgery Department, Taipei
Koo Foundation, Sun Yat-Sen Cancer Center, Taipei
China Medical University Hospital, Taichung
Division of Therapeutic Radiology and Oncology, Department of Radiology, Muang
Department of Medicine, Faculty of Medicine, Naresuan University, Muang
Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing
307 Hospital of PLA, Beijing
Beijing Cancer Hospital, Beijing
Peking University Third Hospital/Department of Oncology, Beijing
Chinese PLA General Hospital/Oncology, Beijing
The First Hospital of China Medical University/Oncology Department, Shenyang
Liaoning Province Cancer Hospital, Shenyang
The First Hospital of Jilin University, Changchun
Jilin Provincial Cancer Hospital, Changchun
Harbin Medical University Cancer Hospital/Oncology Department, Harbin
Raffles Cancer Centre, Singapore
Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai
Fudan University Shanghai Cancer Center, Shanghai
Jiangsu Cancer Hospital, Nanjing
Jiangsu Province Hospital, Nanjing
The First Affiliated Hospital of Anhui Medical University, Hefei
The First Affiliated Hospital of Bengbu Medical College/Medical Oncology Department, Bengbu
Parkway Cancer Centre, Singapore
Tianjin Cancer Hospital/Breast cancer department, Tianjin
Tan Tock Seng Hospital, Singapore
Tan Tock Seng Hospital, Singapore
The First Affiliated Hospital of College of Medicine, Zhejiang University, Hangzhou
Sir Run Run Shaw Hospital of College of Medicine of Zhejiang University, Center for Oncology, Hangzhou
Zhejiang Cancer Hospital, Hangzhou
Fujian Medical University Union Hospital/Medical Oncology Department, Fuzhou
Oncology Department, the Second Affiliated Hospital of Third Military Medical University, PLA, Chongqing
The Second Xiangya Hospital of Central South University, Changsha
Hunan Provincial Tumor Hospital/Breast Internal Medicine Department, Changsha
Hubei Cancer Hospital, Wuhan
Henan Cancer Hospital, Zhengzhou
Sun Yat-Sen University Cancer Center, Guangzhou
Zhongshan Ophthalmic Center,Sun Yat-Sen University, Guangzhou
Guangdong Provincial People's Hospital, Guangzhou
Breast Tumor Center, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, Guangzhou
West China Hospital of Sichuan University, Chengdu
The Tumor Hospital of Yunnan Province, Kunming
Fourth Hospital of Hebei Medical University, Shijiazhuang
Department of Clinical Oncology, Hong Kong
Queen Mary Hospital, Hong Kong
Lead Sponsor
Pfizer
INDUSTRY